Outcome of radioiodine therapy without, on or 3 days off carbimazole: A prospective interventional three-group comparison

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 6, 2006, Pages 730-737

  Walter, Martin A ^a   Christ Crain, Mirjam ^a   Schindler, Christian ^b   Müller Brand, Jan ^a   Müller, Beat ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

Anti thyroid drugs; Carbimazole; Graves' disease; Hyperthyroidism; Radioiodine; Toxic nodular goitre

Indexed keywords

CARBIMAZOLE; RADIOACTIVE IODINE; THYROID HORMONE;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG HALF LIFE; DRUG UPTAKE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENDER; HUMAN; HYPERTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; THYROID HORMONE BLOOD LEVEL; THYROID WEIGHT; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TOXIC GOITER; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTITHYROID AGENTS; CARBIMAZOLE; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 33744945294     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0092-8     Document Type: Article

References (27)

1. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metab 1990;70:1518-1524
2. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905-917
3. Clerc J, Izembart M, Dagousset F, Jais JP, Heshmati HM, Chevalier A, et al. Influence of dose selection on absorbed dose profiles in radioiodine treatment of diffuse toxic goiters in patients receiving or not receiving carbimazole. J Nucl Med 1993;34:387-393
4. Sabri O, Zimny M, Schreckenberger M, Reinartz P, Ostwald E, Buell U. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy. Thyroid 1999;9:1181-1188
5. Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K, et al. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 1999;84:1229-1233
6. 131I with pre-treatment with carbimazole for thyrotoxicosis: the Gateshead Protocol. Nucl Med Commun 2004;25:675-682
7. Connell JM, Hilditch TE, Robertson J, Coghill G, Alexander WD. Radioprotective action of carbimazole in radioiodine therapy for thyrotoxicosis - influence of the drug on iodine kinetics. Eur J Nucl Med 1987;13:358-361
8. Goolden AW, Fraser TR. Effect of pretreatment with carbimazole in patients with thyrotoxicosis subsequently treated with radioactive iodine. Br Med J 1969;3:443-444
9. Burch HB, Solomon BL, Wartofsky L, Burman KD. Discontinuing antithyroid drug therapy before ablation with radioiodine in Graves disease. Ann Intern Med 1994;121:553-559
10. Wilson R, McKillop JH, Buchanan LM, Bradley H, Smith WE, Thomson JA. The effect of carbimazole therapy on interleukin 2, interleukin 2 receptors and free radicals. Autoimmunity 1990;8:3-7
11. Abalovich M, Llesuy S, Gutierrez S, Repetto M. Peripheral parameters of oxidative stress in Graves' disease: the effects of methimazole and 131 iodine treatments. Clin Endocrinol (Oxf) 2003;59:321-327
12. Nordyke RA, Gilbert FI Jr. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. J Nucl Med 1991;32:411-416
13. Sabri O, Zimny M, Schreckenberger M, Reinartz P, Nowak B, Ostwald E, et al. Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents. Nuklearmedizin 2001;40:1-6
14. Walter MA, Christ-Crain M, Muller B, Muller-Brand J. Radioiodine uptake and thyroid hormone levels on or off simultaneous carbimazole medication: a prospective paired comparison. Nuklearmedizin 2005;44:33-36
15. Toft AD. Clinical practice. Subclinical hyperthyroidism. N Engl J Med 2001;345:512-516
16. Walter MA, Christ-Crain M, Eckard B, Schindler C, Nitzsche EU, Muller-Brand J, et al. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Eur J Clin Invest 2004;34:365-370
17. Bockisch A, Jamitzky T, Derwanz R, Biersack HJ. Optimized dose planning of radioiodine therapy of benign thyroidal diseases. J Nucl Med 1993;34:1632-1638
18. Marinelli LD. Dosage determination in the use of radioactive isotopes. J Clin Invest 1949;28:1271-1280
19. Crooks J, Wayne EJ, Robb RA. A clinical method of assessing the results of therapy in thyrotoxicosis. Lancet 1960;1:397-401
20. Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998;83:685-687
21. Korber C, Schneider P, Korber-Hafner N, Hanscheid H, Reiners C. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre? Eur J Nucl Med 2001;28:1360-1364
22. 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab 2004;89:4439-4444
23. Hancock LD, Tuttle RM, LeMar H, Bauman J, Patience T. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease. Clin Endocrinol (Oxf) 1997;47:425-430
24. Tuttle RM, Patience T, Budd S. Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. Thyroid 1995;5:243-247
25. Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease. Thyroid 2004;14:525-530
26. Marcocci C, Gianchecchi D, Masini I, Golia F, Ceccarelli C, Bracci E, et al. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism. J Endocrinol Invest 1990;13:513-520
27. 131I therapy for hyperthyroidism in patients not pretreated with antithyroid drugs. Neth J Med 1999;55:215-221